Search filters
 Trial Filters
Clear All

Phase

  • 2
  • 2
  • 4
  • 3
  • 1
  • 4

Atopic Dermatitis Clinical Trials

A listing of Atopic Dermatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 4 clinical trials
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric patients with moderate to severe atopic dermatitis (AD) treated with dupilumab Secondary Objectives: Evaluate changes in skin barrier function with TEWL assessed after STS in …

Phase 4
Learn more
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Primary Objective: Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus Secondary Objectives: Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus To …

Phase 4
Learn more
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

This is a parallel, treatment, Phase 2, double-blind, 2-arm study in adult participants (aged at least 18 years) with moderate-to-severe atopic dermatitis (AD) and intolerance or inadequate response to topical corticosteroids (TCS). The total study duration per participant is expected to be approximately 21 weeks, including: Screening: up to 4 …

Phase 2
Learn more
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

This is a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary efficacy of PRN473 in up to 40 patients with mild to moderate AD. On Day 1 (Baseline) of the Blinded …

Phase 2
Learn more